Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
about
Current Cervical Carcinoma Screening GuidelinesHuman papillomavirus (HPV) screening and cervical cancer burden. A Brazilian perspectiveEffectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china.Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda.Lower cost strategies for triage of human papillomavirus DNA-positive women.Long-term cumulative detection of human papillomavirus among HIV seropositive women.Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type.Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in AustraliaContributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older womenMajor clinical research advances in gynecologic cancer in 2012.Acceptability and usability of self-collected sampling for HPV testing among African-American women living in the Mississippi DeltaKey considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancerPrimary cervical cancer screening with an HPV mRNA test: a prospective cohort study.Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme.HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway.Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in ChinaABC3 Part I: a review of the guidelines for terminology, classification and management of cervical cytology in England.Worldwide incidence of cervical lesions: a systematic review.Human papillomavirus vaccination: where are we now?Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.Why does cervical cancer occur in a state-of-the-art screening program?Excellent analytical and clinical performance of a dry self-sampling device for human papillomavirus detection in an urban Chinese referral population.Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?Accuracy of cervical cytology: comparison of diagnoses of 100 Pap smears read by four pathologists at three hospitals in Norway.Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.Semi-quantitative HPV viral load in patients with ASC-US cytology: viral load correlates strongly with the presence of CIN but only weakly with its severity.A cocktail of p16INK4a and Ki-67, p16INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening.Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach.HPV types in cervical cancer tissue in South Africa: A head-to-head comparison by mRNA and DNA tests.The Next Generation of Cervical Cancer Screening: Should Guidelines Focus on Best Practices for the Future or Current Screening Capacity?
P2860
Q26799522-58AC903A-7661-4945-8B37-6AB33C86412BQ26799791-17000A0E-537A-417D-9E54-B5F08D93FB52Q30278596-198758ED-3A14-4795-A688-CFEB021BCB8CQ30388952-F695FE6A-B5DB-4946-B08F-447E21892E06Q34516596-47F731EC-7CF9-4AAD-B4C4-6D640B7C6D37Q34899459-C46720D2-C905-474E-A2D6-57083E09636AQ35665790-27936B4C-AC80-423D-93CD-895AB62682C4Q36251151-935320DF-1CF5-43BB-9BEB-027BAE570E39Q36442227-145A04EE-F258-4252-B865-AC5586F3658DQ36547047-406DD6C7-D20B-4F6E-ABA1-E0DAF70BB8A0Q36681189-42994774-C2BF-49DF-980E-213E7DA55B8EQ36698833-4442EFEA-17B0-4034-A844-1A2D8699F968Q37177735-F8449709-0C41-4AA1-AD46-C7452D33E3AAQ37225246-1483AA45-FC45-425B-8C2D-53EC16300B6EQ37516596-BA553140-9119-4A38-BFB8-1A40A065812BQ37595281-F33AF2A3-D7C5-4154-A488-8480C9388622Q37696379-2EA442B4-D0E4-4F2A-B291-6E99682343EBQ38061688-4450E171-2B8A-445F-8CD7-00CCDFB1E06BQ38216073-6E75231A-EB15-44CF-B6E8-8465EE717C67Q38218612-B3DE71A9-BC04-4E09-9D15-7EE9C2AC57BDQ39477130-D8CD18AA-B453-484C-8A52-328BA383173FQ40162758-1639E52D-4ABC-438E-9BDD-AA312848A7B0Q40406285-45F7ACDA-0A7B-4FA8-A96A-2B82109C9E2BQ40569845-F801C806-8E2B-4FA3-AF0B-D8D94FEA4BB5Q40717962-B6F6F6D1-F8F7-44FC-AF5F-47774D18DD39Q41558309-FC1F04FD-4D2C-4E7F-A791-B148B3FA03B1Q41620477-A8F6C7AB-5287-42BB-9053-D75EB95987FFQ42222319-7D2DB3FD-1211-4D32-964C-F674C22ECB03Q45746736-C1F11E34-3420-4B0F-89BE-C0940A0C1E88Q46335294-E23A4534-3E86-4570-970A-04CE42CC3213Q47321818-127FF115-0146-4718-B508-69F4ABC9F554Q55262796-D14F6690-4AA9-4804-9F03-A3BB8E8AEC6F
P2860
Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical human papillomavirus ...... en over 18 years of follow-up.
@en
Clinical human papillomavirus ...... en over 18 years of follow-up.
@nl
type
label
Clinical human papillomavirus ...... en over 18 years of follow-up.
@en
Clinical human papillomavirus ...... en over 18 years of follow-up.
@nl
prefLabel
Clinical human papillomavirus ...... en over 18 years of follow-up.
@en
Clinical human papillomavirus ...... en over 18 years of follow-up.
@nl
P2093
P2860
P356
P1476
Clinical human papillomavirus ...... en over 18 years of follow-up.
@en
P2093
Andrew G Glass
Attila T Lorincz
Brenda B Rush
David R Scott
Greg Rydzak
Julia C Gage
Julie Buckland
Philip E Castle
P2860
P304
P356
10.1200/JCO.2011.38.8389
P407
P577
2012-07-30T00:00:00Z